Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H7Z6
UPID:
KAT8_HUMAN
Alternative names:
Lysine acetyltransferase 8; MOZ, YBF2/SAS3, SAS2 and TIP60 protein 1
Alternative UPACC:
Q9H7Z6; A8K4Z1; G5E9P2; Q659G0; Q7LC17; Q8IY59; Q8WYB4; Q8WZ14; Q9HAC5; Q9NR35
Background:
Histone acetyltransferase KAT8, also known as Lysine acetyltransferase 8, plays a pivotal role in transcriptional activation by acetylating nucleosomal histone H4. This modification, particularly at H4K16, is crucial for chromatin structure and function, influencing gene expression. KAT8's activity extends to non-histone targets, such as TP53, highlighting its versatile role in cellular processes.
Therapeutic significance:
KAT8's mutation is linked to Li-Ghorbani-Weisz-Hubshman syndrome, characterized by developmental delays, intellectual disability, and brain abnormalities. Understanding KAT8's function and its dysregulation offers a pathway to targeted therapies for this syndrome, emphasizing the protein's therapeutic potential.